1 results match your criteria: "Yamaguchi Prefectural Hospital[Affiliation]"
Efficacy of the tyrosine kinase inhibitor gefitinib in a patient with metastatic small cell lung cancer.
Lung Cancer
April 2005
Department of Respiratory Medicine, Yamaguchi Prefectural Hospital, 77 Osaki, Hofu, Yamaguchi 0835-4411, Japan.
Article Synopsis
- Gefitinib is an oral drug that selectively targets the epidermal growth factor receptor tyrosine kinase, primarily used for non-small cell lung cancer (NSCLC).
- There hasn’t been any prior documentation of gefitinib's effects on small-cell lung cancer (SCLC) patients.
- This case report notes a successful treatment with gefitinib in a metastatic SCLC patient, suggesting it may be a new treatment option for certain SCLC cases.